UniProt ID | SIR4_HUMAN | |
---|---|---|
UniProt AC | Q9Y6E7 | |
Protein Name | NAD-dependent protein lipoamidase sirtuin-4, mitochondrial {ECO:0000255|HAMAP-Rule:MF_03161, ECO:0000303|PubMed:25525879} | |
Gene Name | SIRT4 {ECO:0000255|HAMAP-Rule:MF_03161, ECO:0000312|HGNC:HGNC:14932} | |
Organism | Homo sapiens (Human). | |
Sequence Length | 314 | |
Subcellular Localization | Mitochondrion matrix . | |
Protein Description | Acts as NAD-dependent protein lipoamidase, ADP-ribosyl transferase and deacetylase. Catalyzes more efficiently removal of lipoyl- and biotinyl- than acetyl-lysine modifications. Inhibits the pyruvate dehydrogenase complex (PDH) activity via the enzymatic hydrolysis of the lipoamide cofactor from the E2 component, DLAT, in a phosphorylation-independent manner. [PubMed: 25525879 Catalyzes the transfer of ADP-ribosyl groups onto target proteins, including mitochondrial GLUD1, inhibiting GLUD1 enzyme activity. Acts as a negative regulator of mitochondrial glutamine metabolism by mediating mono ADP-ribosylation of GLUD1: expressed in response to DNA damage and negatively regulates anaplerosis by inhibiting GLUD1, leading to block metabolism of glutamine into tricarboxylic acid cycle and promoting cell cycle arrest] | |
Protein Sequence | MKMSFALTFRSAKGRWIANPSQPCSKASIGLFVPASPPLDPEKVKELQRFITLSKRLLVMTGAGISTESGIPDYRSEKVGLYARTDRRPIQHGDFVRSAPIRQRYWARNFVGWPQFSSHQPNPAHWALSTWEKLGKLYWLVTQNVDALHTKAGSRRLTELHGCMDRVLCLDCGEQTPRGVLQERFQVLNPTWSAEAHGLAPDGDVFLSEEQVRSFQVPTCVQCGGHLKPDVVFFGDTVNPDKVDFVHKRVKEADSLLVVGSSLQVYSGYRFILTAWEKKLPIAILNIGPTRSDDLACLKLNSRCGELLPLIDPC | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
13 | Acetylation | ALTFRSAKGRWIANP EEEEECCCCCEEECC | 50.70 | 12432727 | |
26 | Acetylation | NPSQPCSKASIGLFV CCCCCCCCCEEEEEE | 53.52 | 12432737 | |
43 | Acetylation | SPPLDPEKVKELQRF CCCCCHHHHHHHHHH | 65.09 | 12432745 | |
61 | Phosphorylation | SKRLLVMTGAGISTE HHHHHHHCCCCCCCC | 19.19 | 23532336 | |
69 | Phosphorylation | GAGISTESGIPDYRS CCCCCCCCCCCCHHH | 41.95 | 23532336 | |
78 | Ubiquitination | IPDYRSEKVGLYART CCCHHHHCCEEEEEC | 42.73 | - | |
255 | Phosphorylation | KRVKEADSLLVVGSS HHHHHCCEEEEECCE | 30.56 | 17924679 | |
261 | Phosphorylation | DSLLVVGSSLQVYSG CEEEEECCEEEEECC | 19.10 | 17924679 | |
262 | Phosphorylation | SLLVVGSSLQVYSGY EEEEECCEEEEECCC | 19.52 | 17924679 | |
299 | Ubiquitination | SDDLACLKLNSRCGE CCHHHHHHCCCCCCC | 45.57 | 29967540 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of SIR4_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of SIR4_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of SIR4_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
SIR3_HUMAN | SIRT3 | physical | 17715127 | |
IDE_HUMAN | IDE | physical | 17715127 | |
ADT2_HUMAN | SLC25A5 | physical | 17715127 | |
ADT3_HUMAN | SLC25A6 | physical | 17715127 | |
DHE3_MOUSE | Glud1 | physical | 16959573 | |
CH60_HUMAN | HSPD1 | physical | 26186194 | |
SNX3_HUMAN | SNX3 | physical | 26186194 | |
CH60_HUMAN | HSPD1 | physical | 28514442 | |
SNX3_HUMAN | SNX3 | physical | 28514442 | |
FANCA_HUMAN | FANCA | physical | 28215707 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-255; SER-261 ANDSER-262, AND MASS SPECTROMETRY. |